Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pluri Inc. (PLUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: PLUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.05% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.87M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.57 | 52 Weeks Range 3.33 - 7.13 | Updated Date 11/5/2025 |
52 Weeks Range 3.33 - 7.13 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1663.57% |
Management Effectiveness
Return on Assets (TTM) -35.44% | Return on Equity (TTM) -1021.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 51769955 | Price to Sales(TTM) 21.61 |
Enterprise Value 51769955 | Price to Sales(TTM) 21.61 | ||
Enterprise Value to Revenue 38.75 | Enterprise Value to EBITDA -1.28 | Shares Outstanding 8155948 | Shares Floating 3427700 |
Shares Outstanding 8155948 | Shares Floating 3427700 | ||
Percent Insiders 36.36 | Percent Institutions 17.18 |
Upturn AI SWOT
Pluri Inc.
Company Overview
History and Background
Pluri Inc., formerly Pluri StemCells Inc., focuses on cell therapy technology. Founded in 2003, it has evolved from initial stem cell research to developing cell-based products for various medical conditions.
Core Business Areas
- Cell Therapy Development: Developing and manufacturing cell-based products for regenerative medicine applications, targeting conditions such as acute radiation syndrome and muscle regeneration.
- CD34+ Cell Technology: Utilizing its proprietary technology to expand CD34+ cells from various sources, offering potential therapeutic solutions.
Leadership and Structure
Pluri Inc.'s leadership team consists of experienced professionals in biotechnology and pharmaceuticals. The organizational structure includes research and development, manufacturing, and clinical operations departments.
Top Products and Market Share
Key Offerings
- PLX-R18: A cell therapy product being developed for the treatment of Acute Radiation Syndrome (ARS), as well as for incomplete recovery of blood systems following Hematopoietic Cell Transplantation (HCT). While specific market share data is unavailable, competitors include companies developing supportive care therapies for ARS.
- PLX-PAD: A cell therapy product being developed for muscle regeneration and bone marrow regeneration. There are few cell-based therapies in this area making the market relatively new. Competitors would include companies making more traditional treatments for bone marrow failure.
Market Dynamics
Industry Overview
The cell therapy market is experiencing rapid growth, driven by advancements in regenerative medicine and the increasing prevalence of chronic diseases. This sector is highly competitive and requires significant capital investment for research, clinical trials, and regulatory approvals.
Positioning
Pluri Inc. aims to establish itself as a leader in cell therapy by leveraging its proprietary technology and focusing on areas with unmet medical needs. It strives to create safe and effective cellular products that offer clinical benefits to patients.
Total Addressable Market (TAM)
The cell therapy market is projected to reach billions of dollars in the coming years. Pluri Inc. aims to capture a significant portion of this TAM through its targeted therapies, focusing on specific applications.
Upturn SWOT Analysis
Strengths
- Proprietary cell expansion technology
- Strong pipeline of cell therapy candidates
- Experienced management team
- Established manufacturing capabilities
Weaknesses
- Limited financial resources
- Dependence on external funding
- Regulatory hurdles in cell therapy approval
- Small company size limits market reach.
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Increasing demand for cell-based therapies
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes
- Clinical trial failures
- Difficulty in obtaining funding
Competitors and Market Share
Key Competitors
- MESO
- CRIS
Competitive Landscape
Pluri Inc. faces competition from larger and more established pharmaceutical companies. Its competitive advantage lies in its proprietary technology and focus on specific, underserved markets.
Growth Trajectory and Initiatives
Historical Growth: Growth has been largely driven by advancements in its technology and successful clinical trial milestones.
Future Projections: Future growth will depend on the successful development and commercialization of its cell therapy products, especially PLX-R18.
Recent Initiatives: Recent initiatives include advancing clinical trials for PLX-R18 and PLX-PAD, as well as securing additional funding for research and development.
Summary
Pluri Inc. is a cell therapy company with promising technology and a pipeline of potential products. Its future success depends on successfully navigating regulatory hurdles, securing additional funding, and demonstrating clinical efficacy. Being a microcap company, it is a high-risk investment with the potential for high reward but also the possiblity of significant losses. Pluri Inc. needs to look out for funding opportunities and market uptake of products.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Financial news articles
Disclaimers:
This analysis is for informational purposes only and should not be considered as investment advice. Investment decisions should be based on individual risk tolerance and thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pluri Inc.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2003-06-30 | President, CEO & Director Mr. Yaacov Yanay | ||
Sector Healthcare | Industry Biotechnology | Full time employees 127 | Website https://www.pluri-biotech.com |
Full time employees 127 | Website https://www.pluri-biotech.com | ||
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.